Homoharringtonine and SAHA synergistically enhance apoptosis in human acute myeloid leukemia cells through upregulation of TRAIL and death receptors

Molecular Medicine Reports

Volumn 7, Issue 6, 2013, Pages 1838-1844

  Cao, Hui ^a,b   Cheng, Yizhi ^a   You, Liangshun ^a   Qian, Jiejing ^a   Qian, Wenbin ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Apoptosis; Homoharringtonine; Suberoylanilide hydroxamic acid; Synergy; Tumor necrosis factor related apoptosis inducing ligand

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; DEATH RECEPTOR 4; DEATH RECEPTOR 5; HOMOHARRINGTONINE; PROTEIN P53; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SIZE; CANCER SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; FEMALE; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; APOPTOSIS; CASPASE 8; CASPASE 9; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HARRINGTONINES; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, SCID; RECEPTORS, DEATH DOMAIN; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSPLANTATION, HETEROLOGOUS;

EID: 84877251957     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1440     Document Type: Article

References (35)

1. Taby R and Issa JP: Cancer epigenetics. CA Cancer J Clin 60: 376-392, 2010.
2. Shao Y, Gao Z, Marks PA and Jiang X: Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 101: 18030-18035, 2004.
3. Vrana JA, Decker RH, Johnson CR, et al: Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 18: 7016-7025, 1999.
4. Richon VM, Emiliani S, Verdin E, et al: A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 95: 3003-3007, 1998.
5. Rosato RR, Almenara JA, Maggio SC, et al: Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions. Mol Cancer Ther 7: 3285-3297, 2008.
6. Miller CP, Singh MM, Rivera-Del Valle N, Manton CA and Chandra J: Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors. J Biomed Biotechnol 2011: Jun 28, 2011 (Epub ahead of print).
7. Bali P, Pranpat M, Bradner J, et al: Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 280: 26729-26734, 2005.
8. Redner RL, Wang J and Liu JM: Chromatin remodeling and leukemia: new therapeutic paradigms. Blood 94: 417-428, 1999.
9. Wang J, Saunthararajah Y, Redner RL and Liu JM: Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. Cancer Res 59: 2766-2769, 1999.
10. Garcia-Manero G, Yang H, Bueso-Ramos C, et al: Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 111: 1060-1066, 2008.
11. Schaefer EW, Loaiza-Bonilla A, Juckett M, et al; Mayo P2C Phase II Consortium: A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica 94: 1375-1382, 2009.
12. Shiozawa K, Nakanishi T, Tan M, et al: Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias. Clin Cancer Res 15: 1698-1707, 2009.
13. Kuendgen A, Bug G, Ottmann OG, et al: Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid. Clin Epigenetics 2: 389-399, 2011.
14. Nie D, Huang K, Yin S, et al: Synergistic/additive interaction of valproic acid with bortezomib on proliferation and apoptosis of acute myeloid leukemia cells. Leuk Lymphoma 53: 2487-2495, 2012.
15. McCormack E, Haaland I, Venas G, et al: Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia. Leukemia 26: 910-917, 2012.
16. Xie C, Edwards H, Xu X, et al: Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia. Clin Cancer Res 16: 5499-5510, 2010.
17. Chen R, Guo L, Chen Y, Jiang Y, Wierda WG and Plunkett W: Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia. Blood 117: 156-164, 2011.
18. Lou YJ, Qian WB and Jin J: Homoharringtonine induces apoptosis and growth arrest in human myeloma cells. Leuk Lymphoma 48: 1400-1406, 2007.
19. Legha SS, Keating M, Picket S, Ajani JA, Ewer M and Bodey GP: Phase I clinical investigation of homoharringtonine. Cancer Treat Rep 68: 1085-1091, 1984.
20. Kantarjian HM, Keating MJ, Walters RS, Koller CA, McCredie KB and Freireich EJ: Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia. Cancer 63: 813-817, 1989.
21. Kantarjian HM, Talpaz M, Smith TL, et al: Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. J Clin Oncol 18: 3513-3521, 2000.
22. Wang J, Lü S, Yang J, et al: A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China. J Hematol Oncol 2009: Jul 30, 2009 (Epub ahead of print).
23. Jin J, Jiang DZ, Mai WY, et al: Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia. Leukemia 20: 1361-1367, 2006.
24. Shankar S, Singh TR, Fandy TE, Luetrakul T, Ross DD and Srivastava RK: Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways. Int J Mol Med 16: 1125-1138, 2005.
25. Feldman E, Arlin Z, Ahmed T, et al: Homoharringtonine is safe and effective for patients with acute myelogenous leukemia. Leukemia 6: 1185-1188, 1992.
26. Kelly WK, O'Connor OA, Krug LM, et al: Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23: 3923-3931, 2005.
27. Lévy V, Zohar S, Bardin C, et al: A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia. Br J Cancer 95: 253-259, 2006.
28. Luo CY, Tang JY and Wang YP: Homoharringtonine: a new treatment option for myeloid leukemia. Hematology 9: 259-270, 2004.
29. Chan YP, Lee FW and Siu TS: Quantitation of homoharringtonine in plasma by high-performance liquid chromatography with amperometric detection. J Chromatogr 496: 155-166, 1989.
30. Cai Z, Lin M, Wuchter C, et al: Apoptotic response to homoharringtonine in human wt p53 leukemic cells is independent of reactive oxygen species generation and implicates Bax translocation, mitochondrial cytochrome c release and caspase activation. Leukemia 15: 567-574, 2001.
31. Yin S, Wang R, Zhou F, Zhang H and Jing Y: Bcl-xL is a dominant antiapoptotic protein that inhibits homoharringtonine-induced apoptosis in leukemia cells. Mol Pharmacol 79: 1072-1083, 2011.
32. Kaufmann SH and Steensma DP: On the TRAIL of a new therapy for leukemia. Leukemia 19: 2195-2202, 2005.
33. Riccioni R, Pasquini L, Mariani G, et al: TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica 90: 612-624, 2005.
34. Jones DT, Ganeshaguru K, Mitchell WA, et al: Cytotoxic drugs enhance the ex vivo sensitivity of malignant cells from a subset of acute myeloid leukaemia patients to apoptosis induction by tumour necrosis factor receptor-related apoptosis-inducing ligand. Br J Haematol 121: 713-720, 2003.
35. Min YJ, Lee JH, Choi SJ, et al: Prognostic significance of Fas (CD95) and TRAIL receptors (DR4/DR5) expression in acute myelogenous leukemia. Leuk Res 28: 359-365, 2004.